Stock comparison
LeMaitre Vascular
Moderna
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
MRNA
Moderna
Market cap
$18.6B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | MRNA | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 21F | LMAT |
| Benjamin Graham | 89A | 47D | LMAT |
| Philip Fisher | 81C | 27F | LMAT |
| Peter Lynch | 67B | 4F | LMAT |
| Joel Greenblatt | 56D | 2F | LMAT |
| Charlie Munger | 68D | 19F | LMAT |
| Terry Smith | 69D | 19F | LMAT |
Side-by-side metrics
| Metric | LMAT | MRNA |
|---|---|---|
| Market cap | $2.23B | $18.6B |
| P/E (TTM) | 37.1x | - |
| EV/EBIT | 36.6x | - |
| ROIC (TTM) | 9.43% | -37.32% |
| Gross margin | 72.39% | -13.89% |
| Net margin | 24.35% | -143.55% |
| Revenue CAGR 5y | 12.75% | -42.46% |
| EPS CAGR 5y | 19.04% | - |
| Debt / Equity | 0.5x | 0.2x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Revenue CAGR 5y12.75%vs -42.46%+130%
- ROIC (TTM)9.43%vs -37.32%+125%
- Gross margin72.39%vs -13.89%+119%
- Net margin24.35%vs -143.55%+117%
MRNA leads on
- EV/EBIT-vs 36.6x+117%
- P/E (TTM)-vs 37.1x+116%
- Market cap$18.6Bvs $2.23B+88%
- Debt / Equity0.2xvs 0.5x+62%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.